WATCHMAN FLX
Total Payments
$4.7M
Transactions
41,946
Doctors
17,236
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.7M | 28,978 | 13,121 |
| 2023 | $1.0M | 12,966 | 7,465 |
| 2022 | $58.86 | 2 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 17 | 41.3% |
| Food and Beverage | $1.6M | 41,041 | 34.4% |
| Consulting Fee | $525,413 | 169 | 11.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $426,240 | 227 | 9.0% |
| Travel and Lodging | $203,147 | 486 | 4.3% |
| Education | $591.88 | 5 | 0.0% |
| Grant | $50.00 | 1 | 0.0% |
Payments by Type
General
$2.8M
41,929 transactions
Research
$2.0M
17 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| WATCHMAN FLX Real World Evidence Protocol | Boston Scientific Corporation | $1.1M | 0 |
| Direct Comparison of Cardiac CT with TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics: A Multicenter Study | Boston Scientific Corporation | $402,488 | 0 |
| Safety and efficacy of a high-volume WATCHMAN day | Boston Scientific Corporation | $340,661 | 0 |
| Left Atrial Appendage closure with WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding The GI FLX Registry | Boston Scientific Corporation | $74,269 | 0 |
| Efficacy of short-term dabigatran etexilate followed by aspirin monotherapy after LAA (left atrial appendage) device closure (the DEA-LAA study) | Boston Scientific Corporation | $35,993 | 0 |
| WATCHOUT | Boston Scientific Corporation | $16,732 | 0 |
| Efficacy of short term dabigatran etexilate followed by aspirin monotherapy after LAA left atrial appendage device closure the DEA LAA study | Boston Scientific Corporation | $6,000 | 0 |
Top Doctors Receiving Payments for WATCHMAN FLX — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Clinical Cardiac Electrophysiology | Miami, FL | $7,339 | 19 |
| , AG-ACNP | Acute Care | Phoenix, AZ | $6,857 | 29 |
| , M.D | Internal Medicine | Ponce, PR | $6,469 | 12 |
| Suleyka Olivero-Rivera | Hospitalist | Ponce, PR | $6,099 | 11 |
| , M.D | Cardiovascular Disease | Sacramento, CA | $5,822 | 11 |
| , MD | Interventional Cardiology | Wormleysburg, PA | $5,565 | 9 |
| , PA | Medical | La Jolla, CA | $5,253 | 14 |
| , MD | Emergency Medicine | Boston, MA | $5,000 | 2 |
| , MD | Interventional Cardiology | Columbus, OH | $4,948 | 11 |
| , MD | Cardiovascular Disease | Pinehurst, NC | $4,859 | 47 |
| , MD | Cardiovascular Disease | Kansas City, MO | $4,847 | 16 |
| , D.O | Clinical Cardiac Electrophysiology | Lexington, KY | $4,396 | 4 |
| , MD | Internal Medicine | San Juan, PR | $4,394 | 7 |
| , MD FACC | Cardiovascular Disease | Cincinnati, OH | $4,107 | 7 |
| , M.D | Cardiovascular Disease | Chesapeake, VA | $4,038 | 4 |
| , MD | Internal Medicine | Fort Collins, CO | $4,004 | 2 |
| , MD | Internal Medicine | Ann Arbor, MI | $4,000 | 1 |
| , MD | Internal Medicine | New York, NY | $3,969 | 7 |
| , M.D | Internal Medicine | San Juan, PR | $3,818 | 6 |
| , ARNP | Adult Health | Tampa, FL | $3,480 | 15 |
| , M.D | Cardiovascular Disease | Tulsa, OK | $3,287 | 7 |
| , M.D | Interventional Cardiology | Charleston, SC | $3,118 | 23 |
| , M.D | Cardiovascular Disease | Anderson, SC | $3,068 | 35 |
| , ANP | Adult Health | Raleigh, NC | $2,847 | 37 |
| , N.P | Nurse Practitioner | Raleigh, NC | $2,789 | 38 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $4.7M
- Total Doctors 17,236
- Transactions 41,946
About WATCHMAN FLX
WATCHMAN FLX is a device associated with $4.7M in payments to 17,236 healthcare providers, recorded across 41,946 transactions in the CMS Open Payments database. The primary manufacturer is Boston Scientific Corporation.
Payment data is available from 2022 to 2024. In 2024, $3.7M was paid across 28,978 transactions to 13,121 doctors.
The most common payment nature for WATCHMAN FLX is "Unspecified" ($2.0M, 41.3% of total).
WATCHMAN FLX is associated with 7 research studies, including "WATCHMAN FLX Real World Evidence Protocol" ($1.1M).